U.S. markets closed

Stepan Company (SCL)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
123.53-1.95 (-1.55%)
At close: 4:00PM EDT
123.53 +0.01 (0.01%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close125.48
Open125.28
Bid123.87 x 1000
Ask124.10 x 800
Day's Range123.51 - 126.09
52 Week Range87.60 - 139.30
Volume73,773
Avg. Volume61,053
Market Cap2.782B
Beta (5Y Monthly)0.71
PE Ratio (TTM)20.55
EPS (TTM)6.01
Earnings DateJul 20, 2021 - Jul 26, 2021
Forward Dividend & Yield1.22 (0.97%)
Ex-Dividend DateMay 27, 2021
1y Target Est141.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-18% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Stepan Company (SCL) Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Stepan Company (SCL) Sees Hammer Chart Pattern: Time to Buy?

    Stepan Company (SCL) has been struggling lately, but the selling pressure may be coming to an end soon

  • Stepan Announces $100 Million Notes Offerings
    PR Newswire

    Stepan Announces $100 Million Notes Offerings

    Stepan Company (NYSE: SCL) announced today that on June 10, 2021, it issued $50 million in aggregate principal amount of its 2.30% Senior Notes, Series 2021-A, due June 10, 2028, and entered into an agreement to issue $50 million in aggregate principal amount of its 2.37% Senior Notes, Series 2021–B, due September 23, 2028. The Series 2021-B Notes offering is expected to close on September 23, 2021, subject to customary closing conditions. Stepan intends to use the net proceeds from the issuance

  • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
    GlobeNewswire

    AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

    VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in